The Limited Times

Now you can see non-English news...

Coronavirus research: drug shows first clear successes - expansion of use planned

2020-05-24T06:15:09.752Z


Coronavirus drugs: Remdesivir vs. Hydroxychloroquine - Research shows clear trends for efficacy - approvals are also being extended in Europe. 


Coronavirus drugs: Remdesivir vs. Hydroxychloroquine - Research shows clear trends for efficacy - approvals are also being extended in Europe. 

  • Medicines are searched worldwide in connection with the coronavirus * .
  • Research * is apparently making progress.
  • A study from the USA now shows clear successes with the use of the drug remdesivir .
  • Here you will find the basic facts about the corona virus * and the corona news from Germany. We also offer you the current number of cases in Germany on a map. The following recommendations for corona protective measures * are currently available.

USA - While the number of worldwide from infection with the coronavirus has increased convalescent to over two million, should reduce the number of new cases still remain on high worldwide. South America in particular is moving into focus: after b, it has now replaced Europe as the focus of the pandemic.

As time progresses, more and more studies on therapeutic approaches and treatment options are published. They confirm initial assumptions - or dispel myths. Two recent findings give hope that doctors will soon have more clarity.

Coronavirus drug: Extension of approval in Europe could be imminent

As the ZDF writes, there are two main trends: According to this, the drug hydroxychloroquine , which was originally developed for malaria, had serious side effects, especially for people with heart problems, and increased mortality rates. At the same time, there would be confirmation of treatment success with another drug that was originally intended to be used against Ebola. 

Accordingly, clear treatment successes are particularly evident : the death rate after using Remdesivir - compared to placebo - is somewhat lower, the recovery time is 31 percent lower. In the United States, the  US biotech group Gilead has already received approval for the drug in emergencies. And the EU drug agency EMA could soon follow suit. In a hearing before the EU Parliament last week, it was certified that experts rate the study data available so far as "robust enough". If this is the case, a conditional market approval could be imminent. The medication may already be used in Europe for inpatients who are not ventilated.

A study on Remdesivir * has also been running in Germany for some time. The drug is being researched at eight German university clinics. Also in Munich. Here the drug helped about every second patient, reported Professor Wendtner, chief physician of infectiology at the Munich clinic in Schwabing.

Coronavirus drug: Research goes in different directions

A publication by the National Health Institute in the USA (NIH) shows that testing is continuing in different directions at university clinics and in cooperation with various pharmaceutical companies: on May 14, it was confirmed that another study on hydroxychloroquine should also start. The doctors apparently hope to find out about the effects in connection with the antibiotic azithromycin . The participants in the study should take the medication at home and document their condition.

Report about our work @MpiciPotsdam @BioMolSys on sorting out whether artemisia annua extracts and pure substances might actually work against coronavirus. We need to get certainty at a time when entire countries are beginning to use untested extracts. https://t.co/1E4wCWFW67

- Peter Seeberger (@peterseeberger) May 14, 2020

Meanwhile, researchers from the Max Planck Institute in Berlin are following another trail . Here it is examined whether extracts of artemisinin (or mugwort) could prove to be effective. A medicinal potion based on this plant is now marketed worldwide from Madagascar - since scientific evidence has so far been lacking, researchers at the Max Planck Institute hope for more clarity here.

* merkur.de is part of the nationwide Ippen-Digital editors network

Rubric list picture: © dpa

Source: merkur

All news articles on 2020-05-24

You may like

News/Politics 2024-03-02T19:44:31.282Z
News/Politics 2024-03-02T19:45:05.504Z

Trends 24h

News/Politics 2024-03-27T16:45:54.081Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.